Key result
This review highlights pitfalls in assays for detecting anti-interferon antibodies in multiple sclerosis and emphasizes the need for individualized medicine over standardized regimens.
Population
Patients with multiple sclerosis treated with human recombinant interferon-beta
Design
Review
Authors
Loading...
Assay pitfalls warrant cautious interpretation of anti-interferon antibodies in MS; leaves open optimal individualized regimens pending validation.
This review emphasizes the complexities of detecting anti-interferon antibodies in multiple sclerosis and advocates for individualized therapeutic approaches.
Klaus Bendtzen (2010) conducted a review in Multiple Sclerosis. Human recombinant IFN-β was evaluated. This review highlights pitfalls in assays for detecting anti-interferon antibodies in multiple sclerosis and emphasizes the need for individualized medicine over standardized regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: